$VNDA
Vanda Pharmaceuticals Inc.

2013 Q2 Form 10-Q Financial Statement

#000119312513311423 Filed on July 31, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $8.319M $8.378M
YoY Change -0.7% 12.76%
Cost Of Revenue $0.00
YoY Change
Gross Profit $8.320M
YoY Change
Gross Profit Margin 100.01%
Selling, General & Admin $5.260M $3.600M
YoY Change 46.11% 40.08%
% of Gross Profit 63.22%
Research & Development $6.100M $12.49M
YoY Change -51.16% 108.17%
% of Gross Profit 73.32%
Depreciation & Amortization $400.0K $400.0K
YoY Change 0.0% 33.33%
% of Gross Profit 4.81%
Operating Expenses $11.36M $12.49M
YoY Change -9.05% 39.71%
Operating Profit -$3.413M -$8.085M
YoY Change -57.79% 434.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $30.00K $80.00K
YoY Change -62.5% -33.33%
Pretax Income -$3.383M -$8.007M
YoY Change -57.75% 476.04%
Income Tax
% Of Pretax Income
Net Earnings -$3.383M -$8.007M
YoY Change -57.75% 497.09%
Net Earnings / Revenue -40.67% -95.57%
Basic Earnings Per Share -$0.11 -$0.28
Diluted Earnings Per Share -$0.11 -$0.28
COMMON SHARES
Basic Shares Outstanding 28.38M shares 28.23M shares
Diluted Shares Outstanding 28.38M shares 28.23M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.6M $144.7M
YoY Change -28.4% -23.2%
Cash & Equivalents $103.6M $94.39M
Short-Term Investments $0.00 $50.30M
Other Short-Term Assets $3.100M $3.400M
YoY Change -8.82% 41.67%
Inventory $28.00K $200.0K
Prepaid Expenses
Receivables $1.641M $1.700M
Other Receivables $0.00 $0.00
Total Short-Term Assets $108.4M $150.0M
YoY Change -27.76% -21.67%
LONG-TERM ASSETS
Property, Plant & Equipment $2.208M $2.500M
YoY Change -11.68% 150.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $600.0K $1.000M
YoY Change -40.0% -54.55%
Total Long-Term Assets $8.599M $10.80M
YoY Change -20.38% -9.24%
TOTAL ASSETS
Total Short-Term Assets $108.4M $150.0M
Total Long-Term Assets $8.599M $10.80M
Total Assets $117.0M $160.8M
YoY Change -27.27% -20.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.167M $1.700M
YoY Change -31.35% 30.77%
Accrued Expenses $3.770M $5.900M
YoY Change -36.1% 136.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.94M $34.40M
YoY Change -7.17% 4.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $80.00M $106.4M
YoY Change -24.81% -18.78%
Total Long-Term Liabilities $80.00M $106.4M
YoY Change -24.81% -18.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.94M $34.40M
Total Long-Term Liabilities $80.00M $106.4M
Total Liabilities $111.9M $140.8M
YoY Change -20.51% -14.09%
SHAREHOLDERS EQUITY
Retained Earnings -$298.4M
YoY Change
Common Stock $303.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.026M $20.10M
YoY Change
Total Liabilities & Shareholders Equity $117.0M $160.8M
YoY Change -27.27% -20.94%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$3.383M -$8.007M
YoY Change -57.75% 497.09%
Depreciation, Depletion And Amortization $400.0K $400.0K
YoY Change 0.0% 33.33%
Cash From Operating Activities -$8.100M -$12.20M
YoY Change -33.61% 117.86%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$200.0K
YoY Change -50.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $1.000M -$1.300M
YoY Change -176.92% -135.14%
Cash From Investing Activities $900.0K -$1.500M
YoY Change -160.0% -142.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 800.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -8.100M -12.20M
Cash From Investing Activities 900.0K -1.500M
Cash From Financing Activities 800.0K 0.000
Net Change In Cash -6.400M -13.70M
YoY Change -53.28% 552.38%
FREE CASH FLOW
Cash From Operating Activities -$8.100M -$12.20M
Capital Expenditures -$100.0K -$200.0K
Free Cash Flow -$8.000M -$12.00M
YoY Change -33.33% 122.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q3 vnda Lease Occupancy
LeaseOccupancy
21400 sqft
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28483231 shares
CY2012Q2 us-gaap Deferred Revenue
DeferredRevenue
130569000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94388000
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28483231 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28483231 shares
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
76991000
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
574000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
31935000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6321000
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
37000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11265000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1167000
CY2013Q2 us-gaap Restructuring Reserve
RestructuringReserve
59000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1106000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
5026000
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
303357000
CY2013Q2 us-gaap Deferred Revenue
DeferredRevenue
103780000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298359000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
26789000
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3770000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1052000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1133000
CY2013Q2 us-gaap Liabilities
Liabilities
111928000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1079000
CY2013Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6209000
CY2013Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3002000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
28000
CY2013Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
209000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116954000
CY2013Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
430000
CY2013Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
600000
CY2013Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2131000
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1641000
CY2013Q2 us-gaap Inventory Net
InventoryNet
28000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1495000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1495000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
754000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2208000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
552000
CY2013Q2 us-gaap Assets
Assets
116954000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103633000
CY2013Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
60000
CY2013Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5791000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1495000
CY2013Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
12000000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2651000
CY2013Q2 us-gaap Prepaid Insurance
PrepaidInsurance
432000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
108355000
CY2013Q2 vnda Accrued Compensation And Employee Benefits
AccruedCompensationAndEmployeeBenefits
956000
CY2013Q2 vnda Accrued Consulting And Other Professional Fees
AccruedConsultingAndOtherProfessionalFees
1120000
CY2013Q2 vnda Accrued Lease Exit Liability
AccruedLeaseExitLiability
59000
CY2013Q2 vnda Finite Lived Intangible Assets Amortization Expense Net
FiniteLivedIntangibleAssetsAmortizationExpenseNet
5791000
CY2013Q2 vnda Number Of Stock Incentive Plans
NumberOfStockIncentivePlans
2 EquityPlan
CY2013Q2 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
1598000
CY2013Q2 vnda Liabilities Recorded Future License Payments
LiabilitiesRecordedFutureLicensePayments
0
CY2013Q2 vnda Liabilities Recorded Contractual Obligations Relating To License Agreements
LiabilitiesRecordedContractualObligationsRelatingToLicenseAgreements
0
CY2009Q4 vnda Upfront Payment Received Under Sublicense Agreement
UpfrontPaymentReceivedUnderSublicenseAgreement
200000000
CY2009Q4 vnda Potential Future Milestone Payments
PotentialFutureMilestonePayments
265000000
CY2011Q4 us-gaap Restructuring Reserve
RestructuringReserve
740000
CY2011Q4 us-gaap Deferred Revenue
DeferredRevenue
143853000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87923000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28241743 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28241743 shares
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
90275000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32263000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
321000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287000
CY2012Q4 us-gaap Restructuring Reserve
RestructuringReserve
453000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
9905000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
300974000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
117064000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291107000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
26789000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5187000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
10000
CY2012Q4 us-gaap Liabilities
Liabilities
125543000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5468000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3005000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
135448000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
430000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
31631000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
31621000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
600000
CY2012Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3479000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1168000
CY2012Q4 us-gaap Inventory Net
InventoryNet
57000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2348000
CY2012Q4 us-gaap Assets
Assets
135448000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88772000
CY2012Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
276000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6532000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
31631000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
12000000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3967000
CY2012Q4 us-gaap Prepaid Insurance
PrepaidInsurance
155000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
125968000
CY2012Q4 vnda Accrued Compensation And Employee Benefits
AccruedCompensationAndEmployeeBenefits
127000
CY2012Q4 vnda Reversal Of Deferred Rent
ReversalOfDeferredRent
500000
CY2012Q4 vnda Accrued Consulting And Other Professional Fees
AccruedConsultingAndOtherProfessionalFees
386000
CY2012Q4 vnda Accrued Lease Exit Liability
AccruedLeaseExitLiability
453000
CY2012Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
3900000
CY2012Q4 vnda Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
10000
CY2012Q4 vnda Availableforsale Equity Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleEquitySecuritiesGrossUnrealizedLossAccumulatedInInvestments
dei Trading Symbol
TradingSymbol
VNDA
dei Entity Registrant Name
EntityRegistrantName
Vanda Pharmaceuticals Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001347178
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0116 pure
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28361340 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y11D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17168000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4934432 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28361340 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.62 pure
us-gaap Payments For Restructuring
PaymentsForRestructuring
384000
us-gaap Sales Revenue Net
SalesRevenueNet
16387000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
72000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
13284000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-10000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7252000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-121000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
473000
us-gaap Other Income
OtherIncome
76000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
797000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1316000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7262000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7328000
us-gaap Royalty Revenue
RoyaltyRevenue
3103000
us-gaap Net Income Loss
NetIncomeLoss
-7252000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1782000
us-gaap Costs And Expenses
CostsAndExpenses
23715000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9032000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
601000
us-gaap Share Based Compensation
ShareBasedCompensation
1782000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14861000
us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
797000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13284000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1417000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
880000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
206000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
212000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
741000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
31500000
us-gaap Restructuring Charges
RestructuringCharges
10000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1732000
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
13284000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31428000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13942000
vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25 pure
vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75 pure
vnda Initial Stock Options Granted To Directors Vesting And Exercisable Period
InitialStockOptionsGrantedToDirectorsVestingAndExercisablePeriod
P4Y
vnda Optional Lease Termination Year
OptionalLeaseTerminationYear
2023
vnda Patent Protection Extension Period For Drug Components
PatentProtectionExtensionPeriodForDrugComponents
P6M
vnda Potential Pediatric Extension
PotentialPediatricExtension
P6M
vnda Vesting Period
VestingPeriod
P4Y
vnda Subsequent Stock Options Granted To Directors Vesting And Exercisable Period
SubsequentStockOptionsGrantedToDirectorsVestingAndExercisablePeriod
P1Y
vnda Patent Protection Period For Drug Components
PatentProtectionPeriodForDrugComponents
P5Y
vnda Patent Extension Received Under Hatch Waxman Extension
PatentExtensionReceivedUnderHatchWaxmanExtension
P5Y
vnda Tax Obligations Paid In Connection With Settlement Of Restricted Stock Units
TaxObligationsPaidInConnectionWithSettlementOfRestrictedStockUnits
196000
vnda Option Awards Vesting Period
OptionAwardsVestingPeriod
P3Y
vnda Shares Withheld Upon Settlement Of Restricted Stock Units Value
SharesWithheldUponSettlementOfRestrictedStockUnitsValue
196000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0108 pure
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28226743 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y11D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20904000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5201746 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28226743 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.68 pure
us-gaap Sales Revenue Net
SalesRevenueNet
16519000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1993000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
13284000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49967000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-16000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15969000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-282000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
82000
us-gaap Other Income
OtherIncome
433000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
505000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15985000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16402000
us-gaap Royalty Revenue
RoyaltyRevenue
3235000
us-gaap Net Income Loss
NetIncomeLoss
-15969000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-16000
us-gaap Costs And Expenses
CostsAndExpenses
32921000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7510000
us-gaap Share Based Compensation
ShareBasedCompensation
2595000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6465000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1998000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13284000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2527000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
693000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-151000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
424000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
741000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
77331000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2579000
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
13284000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1600000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27369000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24670000
vnda Initial License Fee
InitialLicenseFee
1000000
vnda Future Regulatory Approval And Sales Milestones
FutureRegulatoryApprovalAndSalesMilestones
95000000
vnda Landlord Contributions For Tenant Improvements
LandlordContributionsForTenantImprovements
1825000
vnda Possible Royalties On Net Sales
PossibleRoyaltiesOnNetSales
Low double digits
vnda Pre Approval Milestone Obligation
PreApprovalMilestoneObligation
4000000
CY2011Q3 vnda Renewal Term Of Lease Agreement
RenewalTermOfLeaseAgreement
P5Y
CY2013Q2 vnda Allowance For Tenant Improvements
AllowanceForTenantImprovements
1900000
CY2009Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
12000000
CY2006 vnda Milestone Payment Under License Agreement
MilestonePaymentUnderLicenseAgreement
1000000
CY2006 vnda Percentage Of Future Sublicense Fees Payable
PercentageOfFutureSublicenseFeesPayable
Mid-twenties
CY2007 vnda Milestone Payment Under Sublicense Agreement
MilestonePaymentUnderSublicenseAgreement
5000000
CY2009 vnda Milestone Payment Relating To Regulatory Approval
MilestonePaymentRelatingToRegulatoryApproval
12000000
CY2011 us-gaap Restructuring Charges
RestructuringCharges
-740000
CY2011 vnda General And Administrative Component
GeneralAndAdministrativeComponent
100000
CY2011 vnda Research And Development Component
ResearchAndDevelopmentComponent
600000
CY2011 vnda Lease Termination Penalty Expense
LeaseTerminationPenaltyExpense
700000
CY2004 vnda Future Percentage Of Royalty Payments Based On Net Sales
FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
Low teens
CY2004 vnda Payment As Initial License Fee
PaymentAsInitialLicenseFee
500000
CY2004 vnda Future Royalty Payments Based On Sales
FutureRoyaltyPaymentsBasedOnSales
Mid-twenties
CY2004 vnda Possible Future Milestone Payments
PossibleFutureMilestonePayments
Less than $100.0 million
CY2004 vnda Initial License Fee Paid To Company
InitialLicenseFeePaidToCompany
500000
CY2004 vnda Possible Future Milestone Payment
PossibleFutureMilestonePayment
Less than $40.0 million
CY2012 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y
CY2012 us-gaap Payments For Restructuring
PaymentsForRestructuring
1507000
CY2012 us-gaap Restructuring Charges
RestructuringCharges
-1220000
CY2012 vnda General And Administrative Component
GeneralAndAdministrativeComponent
200000
CY2012 vnda Research And Development Component
ResearchAndDevelopmentComponent
600000
CY2012 vnda Lease Exit Liability
LeaseExitLiability
1300000
CY2012 vnda Lease And Rental Expense From Ceasing Lease
LeaseAndRentalExpenseFromCeasingLease
800000
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28226743 shares
CY2012Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5199705 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28226743 shares
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-8007000
CY2012Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1188000
CY2012Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12490000
CY2012Q2 vnda Initial License Fee
InitialLicenseFee
1000000
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28377254 shares
CY2013Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4118184 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28377254 shares
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
8319000
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
8378000
CY2012Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
6678000
CY2012Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-22000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8007000
CY2012Q2 us-gaap Other Income
OtherIncome
78000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8029000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8085000
CY2012Q2 us-gaap Royalty Revenue
RoyaltyRevenue
1700000
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
16463000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3601000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
CY2012Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
372000
CY2013Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
6678000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3079000
CY2013Q2 us-gaap Other Income
OtherIncome
30000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3079000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3109000
CY2013Q2 us-gaap Royalty Revenue
RoyaltyRevenue
1641000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-3079000
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
11428000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5074000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
CY2013Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
372000
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
788000
CY2013Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5982000

Files In Submission

Name View Source Status
0001193125-13-311423-index-headers.html Edgar Link pending
0001193125-13-311423-index.html Edgar Link pending
0001193125-13-311423.txt Edgar Link pending
0001193125-13-311423-xbrl.zip Edgar Link pending
d542774d10q.htm Edgar Link pending
d542774dex1051.htm Edgar Link pending
d542774dex311.htm Edgar Link pending
d542774dex312.htm Edgar Link pending
d542774dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R45.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R46.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R47.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R48.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R49.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R50.htm Edgar Link pending
R50.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R51.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R52.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R53.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R54.xml Edgar Link unprocessable
R55.htm Edgar Link pending
R55.xml Edgar Link unprocessable
R56.htm Edgar Link pending
R56.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20130630.xml Edgar Link completed
vnda-20130630.xsd Edgar Link pending
vnda-20130630_cal.xml Edgar Link unprocessable
vnda-20130630_def.xml Edgar Link unprocessable
vnda-20130630_lab.xml Edgar Link unprocessable
vnda-20130630_pre.xml Edgar Link unprocessable